Mirum Pharmaceuticals Temettü
Temettü kriter kontrolleri 0/6
Mirum Pharmaceuticals does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-11.3%
Geri Alım Getirisi
Toplam Hissedar Getirisi | -11.3% |
Gelecekteki Temettü Verimi | 0% |
Temettü Büyümesi | n/a |
Bir sonraki temettü ödeme tarihi | n/a |
Eski temettü tarihi | n/a |
Hisse başına temettü | n/a |
Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?
Nov 03Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Oct 04Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth
Jul 13Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if MIRM's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if MIRM's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
Mirum Pharmaceuticals Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (MIRM) | n/a |
Pazarın Alt %25'i (US) | 1.5% |
Pazarın En İyi %25'i (US) | 4.5% |
Sektör Ortalaması (Biotechs) | 2.2% |
Analist tahmini (MIRM) (3 yıla kadar) | 0% |
Önemli Temettü: Unable to evaluate MIRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate MIRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate MIRM's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as MIRM has not reported any payouts.